The compound disrupts RAD52-ssDNA interactions and selectively eliminated BRCA2-mutated pancreatic adenocarcinoma Capan1 cells at the concentration range 10–40 μM, whereas the BRCA2-proficient BxPC3 cell line viability was not significantly influenced. The gene discussed is BRCA2; the disease is pancreatic adenocarcinoma.